Synapse - Paul Paik

Search Within

Paul K Paik

Results (256)

Liquid and tissue biopsies for identifying MET exon 14 skipping NSCLC: Analyses from the phase II VISION study of tepotinib

Journal Article

Rolfo, C.; O’Brate, A.; Menzel, C.; Bruns, R.; Juraeva, D.; Stroh, C.; Johne, A.; Paik, P. K.
Clinical Cancer Research (2025)

Fulltext@MSK | Save

Tepotinib in patients (pts) with METexon 14 (METex14) skipping non-small cell lung cancer (NSCLC) from the VISION study: ≥3-year follow-up outcomes

Meeting Abstract

Mazieres, J.; Veillon, R.; Cortot, A.; Ferrara, R.; Felip, E.; Garassino, M.; Le, X.; Thomas, M.; Sakai, H.; Smit, E.; more...
Journal of Thoracic Oncology (2025)

Fulltext@MSK | Save

A randomized phase III study of ivonescimab versus pembrolizumab as first-line treatment of metastatic non-small cell lung cancer as first-line treatment of metastatic non-small cell lung cancer with high tumor PD-L1 expression: HARMONi-7

Meeting Abstract

Passaro, A.; Girard, N.; Rodriguez Abreu, D.; Gumus, M.; Wu, Y. L.; Syrigos, K.; Ramlau, R.; Santos, E.; Berz, D.; Gandhi, C.; more...
Journal of Thoracic Oncology (2025)

Fulltext@MSK | Save

Tepotinib in patients (pts) with METexon 14 (METex14) skipping non-small cell lung cancer (NSCLC) from the VISION study: ≥3-year follow-up outcomes

Meeting Abstract

Mazieres, J.; Veillon, R.; Cortot, A.; Ferrara, R.; Felip, E.; Garassino, M.; Le, X.; Thomas, M.; Sakai, H.; Smit, E.; more...
Journal of Thoracic Oncology (2025)

Fulltext@MSK | Save

Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma

Journal Article

Lauer, U. M.; Awada, A.; Postel-Vinay, S.; Shapiro, G. I.; Thieblemont, C.; Piha-Paul, S. A.; Paik, P. K.; Shepard, D. R.; Docampo, L. I.; Galot, R.; more...
ESMO Open (2025)

Fulltext@MSK | Save

From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skipping

Review

Bogdanska, W.; Paik, P. K.
Cancer (2025)

Fulltext@MSK | Save

Matching-adjusted indirect comparison (MAIC) of safety outcomes with MET tyrosine kinase inhibitors (TKIs) in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)

Meeting Abstract

Taylor, K.; Veillon, R.; Griesinger, F.; Reinmuth, N.; Ghori, V.; Vioix, H.; Clark, A.; Paik, P.
Value in Health (2024)

Fulltext@MSK | Save

Presenting features and diagnostic delays of NUT carcinoma: A report from the NUT Carcinoma registry

Meeting Abstract

Luo, J.; Walton, S. A.; Kim, J. J.; Paoloni, F.; Liew, J. W.; Cotzany, Z. Z.; Nguyen, T.; Paik, P. K.; Chaft, J. E.; Hsu, R.; more...
Journal of Thoracic Oncology (2024)

Fulltext@MSK | Save

Exploratory analysis of ctDNA and imaging response in the phase I/II CHORUS study of canakinumab with chemoradiation and durvalumab consolidation for stage Ill NSCLC

Meeting Abstract

Shaverdian, N.; Offin, M.; Charalambous, K.; Gelblum, D.; Santini, F.; Boe, L. A.; Shepherd, A. F.; Gewanter, R. M.; Shin, J. Y.; Rimner, A.; more...
International Journal of Radiation Oncology, Biology, Physics (2024)

Fulltext@MSK | Save

Health-related quality of life (HRQoL) with tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) with brain, liver, adrenal or bone metastases in the phase II VISION trial

Meeting Abstract

Gasking, S.; Reinmuth, N.; Mazieres, J.; Popat, S.; Paz-Ares, L.; Hook, E.; Hatswell, A.; Vlassak, S.; Johne, A.; Vioix, H.; more...
Asia-Pacific Journal of Clinical Oncology (2024)

Fulltext@MSK | Save